Trevena to Host Conference Call on March 9th to Discuss Full Year 2015 Financial Results Mar 02, 2016 4:01pm EST
Trevena, Inc. Receives FDA Breakthrough Therapy Designation for Oliceridine for the Management of Moderate-to-Severe Acute Pain Feb 22, 2016 7:00am EST
Trevena to present at the 2016 RBC Capital Markets' Global Healthcare Conference Feb 17, 2016 7:00am EST
Trevena, Inc. Announces Initiation of Oliceridine Phase 3 Clinical Program With Multi-Procedure Safety and Tolerability Study Jan 19, 2016 7:00am EST
Trevena Announces FDA Grant of Fast Track Designation to Oliceridine (TRV130) for the Management of Moderate-to-Severe Acute Pain Dec 03, 2015 4:01pm EST
Trevena Granted Key Composition of Matter and Use Patent for TRV027 in Europe Dec 03, 2015 7:00am EST
